Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia

Schizophrenia Bulletin

Volumn 41, Issue 4, 2015, Pages 900-908

  Buchanan, Robert W ^a   Weiner, Elaine ^a   Kelly, Deanna L ^a   Gold, James M ^a   Keller, William R ^a   Waltz, James A ^a   McMahon, Robert P ^a   Gorelick, David A ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

cognition; dopamine; monoamine oxidase; randomized clinical trial

Indexed keywords

CLOZAPINE; PLACEBO; RASAGILINE; INDAN DERIVATIVE; MONOAMINE OXIDASE INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DSM-IV; FEMALE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE ASSESSMENT; NEGATIVE SYNDROME; NEUROPSYCHOLOGICAL TEST; PANIC; POLYPHARMACY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUICIDAL BEHAVIOR; TASK PERFORMANCE; COGNITION DISORDERS; COMPLICATION; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROCEDURES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

ADULT; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 84936777172     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbu151     Document Type: Article

References (44)

1. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321-330.
2. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72:41-51.
3. Greenwood KE, Landau S, Wykes T. Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy. Schizophr Bull. 2005;31:910-921.
4. Kurtz MM, Moberg PJ, Ragland JD, Gur RC, Gur RE. Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: A 1-and 4-year prospective study. Schizophr Bull. 2005;31:167-174.
5. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: A longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162:495-506.
6. Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull. 2007;33:1013-1022.
7. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007;64:633-647.
8. Marder SR, Fenton W. Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res. 2004;72:5-9.
9. Simon JJ, Biller A, Walther S, et al. Neural correlates of reward processing in schizophrenia-relationship to apathy and depression. Schizophr Res. 2010;118:154-161.
10. Waltz JA, Schweitzer JB, Ross TJ, et al. Abnormal responses to monetary outcomes in cortex, but not in the basal ganglia, in schizophrenia. Neuropsychopharmacology. 2010;35:2427-2439.
11. Waltz JA, Kasanova Z, Ross TJ, et al. The roles of reward, default, and executive control networks in set-shifting impairments in schizophrenia. PLoS One. 2013;8:e57257.
12. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol. 1998;80:1-27.
13. Schultz W. Getting formal with dopamine and reward. Neuron. 2002;36:241-263.
14. Goldman-Rakic PS. Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci. 1994;6:348-357.
15. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl). 2004;174:3-16.
16. Silver H, Aharon N, Hausfater N, Jahjah N. The effect of augmentation with moclobemide on symptoms of schizophrenia. Int Clin Psychopharmacol. 1999;14:193-195.
17. Riederer P, Konradi C, Schay V, et al. Localization of MAO-A and MAO-B in human brain: A step in understanding the therapeutic action of L-deprenyl. Adv Neurol. 1987;45:111-118.
18. Wayment HK, Schenk JO, Sorg BA. Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition. J Neurosci. 2001;21:35-44.
19. Youdim MB, Riederer PF. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Neurology. 2004;63:S32-S35.
20. Perenyi A, Goswami U, Frecska E, Arató M, Bela A. L-deprenyl in treating negative symptoms of schizophrenia. Psychiatry Res. 1992;42:189-191.
21. Bodkin JA, Cohen BM, Salomon MS, Cannon SE, Zornberg GL, Cole JO. Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine. J Nerv Ment Dis. 1996;184:295-301.
22. Gupta S, Droney T, Kyser A, Keller P. Selegiline augmentation of antipsychotics for the treatment of negative symptoms in schizophrenia. Compr Psychiatry. 1999;40:148-150.
23. Jungerman T, Rabinowitz D, Klein E. Deprenyl augmentation for treating negative symptoms of schizophrenia: A double-blind, controlled study. J Clin Psychopharmacol. 1999;19:522-525.
24. Bodkin JA, Siris SG, Bermanzohn PC, Hennen J, Cole JO. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 2005;162:388-390.
25. Amiri A, Noorbala AA, Nejatisafa AA, et al. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study. Hum Psychopharmacol. 2008;23:79-86.
26. Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 2001;132:500-506.
27. Youdim MB, Weinstock M. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol Neurobiol. 2001;21:555-573.
28. Abu-Raya S, Tabakman R, Blaugrund E, Trembovler V, Lazarovici P. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol. 2002;434:109-116.
29. Bar Am O, Amit T, Youdim MB. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett. 2004;355:169-172.
30. First MB, Spitzer RL, Gibbon M, Williams J. Structural Clinical Interview for DSM-IV Axis Disorders (SCID-IV). New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1997.
31. Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull. 2007;33:1013-1022.
32. Buchanan RW, Javitt DC, Marder SR, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007;164:1593-1602.
33. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
34. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990;3:247-251.
35. Gold JM, Queern C, Iannone VN, Buchanan RW. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity. Am J Psychiatry. 1999;156:1944-1950.
36. Cohen JD, Perlstein WM, Braver TS, et al. Temporal dynamics of brain activation during a working memory task. Nature. 1997;386:604-608.
37. Waltz JA, Frank MJ, Robinson BM, Gold JM. Selective reinforcement learning deficits in schizophrenia support predictions from computational models of striatal-cortical dysfunction. Biol Psychiatry. 2007;62:756-764.
38. Kirby KN, Petry NM, Bickel WK. Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. J Exp Psychol Gen. 1999;128:78-87.
39. Kirby KN. Instructions for Inferring Discount Rates From Choices Between Immediate and Delayed Rewards. Williamstown, MA: Williams College; 2000:7.
40. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
41. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
42. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: The TEMPO Study. Arch Neurol. 2002;59:1937-1943.
43. Grant PM, Huh GA, Perivoliotis D, Stolar NM, Beck AT. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia. Arch Gen Psychiatry. 2012;69:121-127.
44. Apud JA, Mattay V, Chen J, et al. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology. 2007;32:1011-1020.